<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567411</url>
  </required_header>
  <id_info>
    <org_study_id>WRAMC WU # 06-23016</org_study_id>
    <nct_id>NCT00567411</nct_id>
  </id_info>
  <brief_title>Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty</brief_title>
  <official_title>Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety and efficacy of two drops used to lower eye
      pressure when given prior to a glaucoma laser procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized double blind trial of patients undergoing selective laser
      trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients
      are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of
      apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled
      patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each
      eye one hour before applying the study medications and at one hour and one week after laser
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative IOP</measure>
    <time_frame>1 hour and 1 week post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall IOP reduction post SLT</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine 0.1%</intervention_name>
    <description>1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apraclonidine 0.5%</intervention_name>
    <description>1 drop applied 1 hour prior to SLT</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, at least 18 years of age

          -  Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of
             progression (based on optic nerve head appearance and/or visual field changes) despite
             current medical therapy

          -  Ocular Hypertension requiring lowering of IOP

          -  ability to understand and provide informed consent to participate in this study and
             willingness to follow study instructions and likely to complete all required visits

        Exclusion Criteria:

          -  inability to understand and provide informed consent to participate in this study

          -  inability/unwillingness to follow study instructions and complete all required visits

          -  Documented allergy to either brimonidine or iopidine

          -  Angle Closure Glaucoma

          -  Congenital/Juvenile Glaucoma

          -  Neovascular Glaucoma

          -  Active uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir S Yakopson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed AMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir S Yakopson, MD</last_name>
    <phone>202-782-6965</phone>
    <email>vladimir.yakopson@na.amedd.army.mil</email>
  </overall_contact>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir S Yakopson, MD</last_name>
      <phone>202-782-6965</phone>
      <email>vladimir.yakopson@na.amedd.army.mil</email>
    </contact>
    <investigator>
      <last_name>William Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>December 4, 2007</last_update_submitted>
  <last_update_submitted_qc>December 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <responsible_party>
    <name_title>Vladimir S Yakopson, MD</name_title>
    <organization>Ophthalmology Service, Department of Surgery, Walter Reed Army Medical Center</organization>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Laser</keyword>
  <keyword>laser trabeculoplasty</keyword>
  <keyword>selective laser trabeculoplasty</keyword>
  <keyword>intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Apraclonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

